Insider Transactions in Q1 2022 at Karyopharm Therapeutics Inc. (KPTI)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2022
|
Sharon Shacham Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
60,000
+5.89%
|
-
|
|
Feb 28
2022
|
Michael Mano SVP, General Counsel&Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
63,000
+50.0%
|
-
|
|
Feb 28
2022
|
Richard A. Paulson President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
288,750
+30.37%
|
-
|
|
Feb 28
2022
|
Sohanya Roshan Cheng EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
84,000
+47.86%
|
-
|
|
Feb 28
2022
|
Stephen Mitchener SVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,250
+48.31%
|
-
|
|
Feb 28
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
6,226
-0.69%
|
$62,260
$10.24 P/Share
|
|
Feb 28
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
6,226
-0.86%
|
$62,260
$10.24 P/Share
|
|
Feb 28
2022
|
Michael Kauffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,000
+2.83%
|
-
|
|
Feb 28
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,226
-0.86%
|
$62,260
$10.24 P/Share
|
|
Feb 28
2022
|
Sharon Shacham Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
21,000
+2.83%
|
-
|
|
Feb 28
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,226
-0.69%
|
$62,260
$10.24 P/Share
|
|
Feb 28
2022
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
2,398
-1.69%
|
$23,980
$10.24 P/Share
|
|
Feb 28
2022
|
Michael Mason EVP, CFO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
88,200
+38.4%
|
-
|
|
Feb 28
2022
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
1,663
-0.98%
|
$16,630
$10.24 P/Share
|
|
Feb 28
2022
|
Ran Frenkel EVP, Chief Dev. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,250
+28.65%
|
-
|
|
Feb 17
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
9,088
-0.99%
|
$109,056
$12.12 P/Share
|
|
Feb 17
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
9,079
-1.28%
|
$108,948
$12.12 P/Share
|
|
Feb 17
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
9,079
-1.28%
|
$108,948
$12.12 P/Share
|
|
Feb 17
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
9,088
-0.99%
|
$109,056
$12.12 P/Share
|
|
Feb 17
2022
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
2,929
-2.8%
|
$35,148
$12.12 P/Share
|
|
Feb 17
2022
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,306
-1.0%
|
$15,672
$12.12 P/Share
|
|
Feb 07
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
6,764
-0.95%
|
$60,876
$9.86 P/Share
|
|
Feb 07
2022
|
Sharon Shacham Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,707
-0.73%
|
$60,363
$9.86 P/Share
|
|
Feb 07
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Indirect |
6,707
-0.73%
|
$60,363
$9.86 P/Share
|
|
Feb 07
2022
|
Michael Kauffman Director |
SELL
Open market or private sale
|
Direct |
6,764
-0.95%
|
$60,876
$9.86 P/Share
|
|
Feb 07
2022
|
Michael Mason EVP, CFO & Treasurer |
SELL
Open market or private sale
|
Direct |
3,947
-6.89%
|
$35,523
$9.86 P/Share
|
|
Feb 07
2022
|
Ran Frenkel EVP, Chief Dev. Officer |
SELL
Open market or private sale
|
Direct |
1,991
-1.87%
|
$17,919
$9.86 P/Share
|
|
Feb 07
2022
|
Jatin Shah EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,704
-1.29%
|
$15,336
$9.86 P/Share
|